The Latest Breaking News from Novo Nordisk

Wegovy makes people feel full so they eat less and lose weight

Thousands are expected to be offered the appetite suppressant Wegovy on prescription

Thousands of people expected to be offered the appetite suppressant popular with celebrities on prescription

Experts described the move as a ‘pivotal moment’ for the treatment of people living with obesity.

The drug shortage is affecting people with Type 2 diabetes, and a surge in cosmetic use is to blame

Arista Networks, which keeps popping up on lists of top AI stocks, leads this weekend's watch list of 5 stocks near buy points.

The cost of 14-year-old Freya Goldston's diabetes medication will soar next month when it's taken off the Pharmaceutical Benefits Scheme and her family don't know if they'll be able to afford it.

The French drug safety agency on Wednesday announced it was stepping up monitoring of Ozempic, a diabetes drug promoted by influencers on social networks who flaunt its weight-loss properties. As well as health concerns, the authorities say the increased demand could jeopardise access for legitimate diabetic patients.

Ozempic has been catapulted into the public eye in recent months as celebrities and wellness influencers started taking it for weight loss. But Ozempic is a diabetes drug — and the craze has led to a shortage, leaving those who need it for Type 2 diabetes at a loss.

Growth stock Novo Nordisk is showing strength after FDA approval of breakthrough oral drug for type 2 diabetes. Shares are in a base.

Under NICE guidelines, Ozempic can only be prescribed to people with Type 2 diabetes who meet certain criteria, such as having a BMI of 30 or more. But the Sunday Mirror discovered the drug can easily be bought online and in beauty salons by people without diabetes.